Compare Stocks: EDIT, CRSP, NTLA, and STOK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$50.10 -2.8%	$55.12	$44.12 ▼ $75.06	$4.98B	1.76	1.84 million shs	1.34 million shs
EDIT Editas Medicine	$2.44 -11.3%	$2.86	$1.66 ▼ $4.33	$422.35M	2	3.41 million shs	2.45 million shs
NTLA Intellia Therapeutics	$11.91 -5.3%	$12.27	$7.95 ▼ $28.25	$1.76B	1.8	5.84 million shs	5.18 million shs
STOK Stoke Therapeutics	$22.50 -6.8%	$29.13	$20.32 ▼ $40.22	$1.56B	1.26	1.02 million shs	617,938 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-3.45%	-10.10%	-0.33%	+2.16%	-29.45%
EDIT Editas Medicine	-5.17%	-1.43%	+1.85%	-12.97%	-26.08%
NTLA Intellia Therapeutics	-3.75%	-1.33%	+7.16%	-5.41%	-48.69%
STOK Stoke Therapeutics	-2.38%	-4.62%	-16.81%	-17.10%	-20.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$50.10 -2.8%	$55.12	$44.12 ▼ $75.06	$4.98B	1.76	1.84 million shs	1.34 million shs
EDIT Editas Medicine	$2.44 -11.3%	$2.86	$1.66 ▼ $4.33	$422.35M	2	3.41 million shs	2.45 million shs
NTLA Intellia Therapeutics	$11.91 -5.3%	$12.27	$7.95 ▼ $28.25	$1.76B	1.8	5.84 million shs	5.18 million shs
STOK Stoke Therapeutics	$22.50 -6.8%	$29.13	$20.32 ▼ $40.22	$1.56B	1.26	1.02 million shs	617,938 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-3.45%	-10.10%	-0.33%	+2.16%	-29.45%
EDIT Editas Medicine	-5.17%	-1.43%	+1.85%	-12.97%	-26.08%
NTLA Intellia Therapeutics	-3.75%	-1.33%	+7.16%	-5.41%	-48.69%
STOK Stoke Therapeutics	-2.38%	-4.62%	-16.81%	-17.10%	-20.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.68	Moderate Buy	$67.50	34.73% Upside
EDIT Editas Medicine	2.71	Moderate Buy	$5.83	139.07% Upside
NTLA Intellia Therapeutics	2.26	Hold	$20.72	73.95% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	96.67% Upside

Current Analyst Ratings Breakdown

Latest EDIT, CRSP, NTLA, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/9/2026	CRSP CRISPR Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/8/2026	EDIT Editas Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Equal Weight ➝ Overweight	$4.00 ➝ $6.00
10/6/2026	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Underweight	$8.00
10/6/2026	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Underweight	$8.00
9/28/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/23/2026	EDIT Editas Medicine	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$5.00
9/23/2026	CRSP CRISPR Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/10/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/9/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$30.00
9/9/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$12.00 ➝ $13.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$3.51M	1,380.11	N/A	N/A	$20.17 per share	2.48
EDIT Editas Medicine	$40.52M	9.25	N/A	N/A	$0.28 per share	8.71
NTLA Intellia Therapeutics	$67.67M	24.66	N/A	N/A	$5.80 per share	2.05
STOK Stoke Therapeutics	$184.42M	7.87	N/A	N/A	$6.17 per share	3.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)

Latest EDIT, CRSP, NTLA, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	CRSP CRISPR Therapeutics	-$1.04	N/A	N/A	N/A	$14.62 million	N/A
11/9/2026	Q3 2026	EDIT Editas Medicine	-$0.21	N/A	N/A	N/A	$4.54 million	N/A
11/5/2026	Q3 2026	NTLA Intellia Therapeutics	-$0.7982	N/A	N/A	N/A	$9.74 million	N/A
11/3/2026	Q3 2026	STOK Stoke Therapeutics	-$0.9291	N/A	N/A	N/A	$8.21 million	N/A
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	0.34	17.85	17.85
EDIT Editas Medicine	N/A	3.19	3.19
NTLA Intellia Therapeutics	N/A	6.65	6.65
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
EDIT Editas Medicine	71.90%
NTLA Intellia Therapeutics	88.77%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	5.20%
EDIT Editas Medicine	3.10%
NTLA Intellia Therapeutics	3.50%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
EDIT Editas Medicine	87	153.58 million	148.82 million	Optionable
NTLA Intellia Therapeutics	377	140.13 million	135.22 million	Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable

EDIT, CRSP, NTLA, and STOK Headlines

Recent News About These Companies

Stoke Therapeutics, Inc. Presents Data Supporting Disease-Modifying Potential Of STK-002 In Autosomal Dominant Optic Atrophy At The American Academy Of Ophthalmology 2026 ...

2 hours ago | marketscreener.comM

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and AbbVie (ABBV)

2 hours ago | theglobeandmail.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 7.1% - Time to Sell?

October 13 at 2:59 PM | marketbeat.com

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO ...

October 12 at 1:41 PM | finance.yahoo.com

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)

October 10 at 1:07 AM | finance.yahoo.com

Stoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual Meeting

October 6, 2026 | marketscreener.comM

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of ...

October 6, 2026 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.9% - What's Next?

October 6, 2026 | marketbeat.com

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

October 6, 2026 | businesswire.com

Stoke Therapeutics, Inc. Announces Completion Of Successful Meeting With The FDA To Align On Planned U.S. NDA For Zorevunersen

October 5, 2026 | marketscreener.comM

Stoke Therapeutics stock heads into November 3 results below key averages

October 5, 2026 | ad-hoc-news.deA

Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA

October 5, 2026 | finance.yahoo.com

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of ...

October 5, 2026 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 627 Shares of Stock

October 3, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,051 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 627 Shares of Stock

October 3, 2026 | insidertrades.com

Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares

October 2, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock

October 2, 2026 | marketbeat.com

Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 27, 2026 | marketbeat.com

Stoke Therapeutics, Inc. Announces Board Changes

September 23, 2026 | marketscreener.comM

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval ...

September 23, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EDIT, CRSP, NTLA, and STOK Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$50.10 -1.45 (-2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$50.20 +0.10 (+0.20%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Editas Medicine NASDAQ:EDIT

$2.44 -0.31 (-11.27%)

Closing price 04:00 PM Eastern

Extended Trading

$2.55 +0.11 (+4.47%)

As of 07:59 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Intellia Therapeutics NASDAQ:NTLA

$11.91 -0.67 (-5.33%)

Closing price 04:00 PM Eastern

Extended Trading

$11.96 +0.04 (+0.38%)

As of 07:54 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$22.50 -1.65 (-6.83%)

Closing price 04:00 PM Eastern

Extended Trading

$22.18 -0.32 (-1.44%)

As of 07:30 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EDIT, CRSP, NTLA, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EDIT, CRSP, NTLA, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EDIT, CRSP, NTLA, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EDIT, CRSP, NTLA, and STOK Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Editas Medicine NASDAQ:EDIT

Intellia Therapeutics NASDAQ:NTLA

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EDIT, CRSP, NTLA, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EDIT, CRSP, NTLA, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EDIT, CRSP, NTLA, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EDIT, CRSP, NTLA, and STOK Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Editas Medicine NASDAQ:EDIT

Intellia Therapeutics NASDAQ:NTLA

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools